Get startedLog in
    Picture of Bayer AG logo

    BAYN — Bayer AG News Story

    0.000.00%
    de flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapMomentum Trap
    All News

    Brief: U.S. FDA Grants Priority Review To Supplemental New Drug Application For Hyrnuo® (Sevabertinib)

    Picture of Bayer AG logoBayer AG
    18/05/2026 14:30
    May 18 (Reuters) - Bayer AG BAYGn.DE:

U.S. FDA GRANTS PRIORITY REVIEW TO SUPPLEMENTAL NEW DRUG APPLICATION FOR HYRNUO® (SEVABERTINIB) UNDER INVESTIGATION AS A FIRST-LINE TREATMENT OF HER2-MUTATED NON-SMALL CELL LUNG CANCER

Source text: ID:nBw98d7SVa

Further company coverage: [BAYGn.DE]

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Bayer AG

    See all news